15 / 31
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
3
6
9
12
15
18
21
24
27
30
33
36
39
Probability of Progression-free Survival
Time from Randomization (months)
No. at Risk
Durvalumab
476
377
302
268
213
188
163
143
116
83
43
23
1
0
Placebo
237
163
106
86
67
55
46
39
32
24
10
5
0
0
PFS HR = 0.51
95% CI, 0.41–0.63
†
34.4%
49.5%
55.7%
26.7%
No. of events /
No. of patients (%)
Median PFS
(95% CI)
months
Durvalumab
243/476 (51.1)
17.2 (13.1–
23.9)
Placebo
173/237 (73.0)
5.6 (4.6–7.7)
0
Overall Survival with Durvalumab versus Placebo after
Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC